Clinical trial
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multi-center Study of Eculizumab for the Prevention of Delayed Graft Function After Kidney Transplantation in Adult Subjects at Increased Risk of Delayed Graft Function.
NCT02145182 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multi-center Study of Eculizumab for the Prevention of Delayed Graft Function After Kidney Transplantation in Adult Subjects at Increased Risk of Delayed Graft Function.
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- August 21, 2014
- Completion date
- November 22, 2016
- Enrollment
- 288 (actual)
- Sites
- 78
Conditions
As the registry lists them; a condition with its own page is linked.